Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse.

No abstract is available for this paper.

• Publication year

  1979

• Venue

  International Journal of Immunopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0192-0561(79)90028-6PMID 551094
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dissociation between the Adjuvant vs Mitogenic Activity of a Synthetic Muramyl Dipeptide for Murine Splenocytes

  1977cited by this paper
• Mycobacterium

  1977cited by this paper
• Synthesis of N-acetylmuramyl-L- [U−14C]alanyl-D-isoglutamine

  1977cited by this paper
• Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs.

  1977cited by this paper
• Modulation of the immune response by a synthetic adjuvant and analogs.

  1976cited by this paper
• Adjuvant activity of synthetic cell-wall peptidoglycan subunits on monoazobenzenearsonate-N-acetyl-L-tyrosine and bacterial alpha-amylase in guinea pigs.

  1976cited by this paper
• Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components.

  1976cited by this paper
• Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids.

  1975cited by this paper
• Cell walls of mycobacteria and related organisms; Chemistry and immunostimulant properties

  1975cited by this paper
• Total synthesis and adjuvant activity of bacterial peptidoglycan derivatives.

  1975cited by this paper
• Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.

  1974cited by this paper
• Peptidoglycan types of bacterial cell walls and their taxonomic implications

  1972cited by this paper
• Enzymes that degrade bacterial cell walls

  1966cited by this paper
• [Study of the tolerance of adrenalectomized mice using an endotoxin labeled with Cr-51].

  1961cited by this paper

• Distinctive Immune Signatures Driven by Structural Alterations in Desmuramylpeptide NOD2 Agonists

  2024cites this paper
• Highlights into historical and current immune interventions for cancer.

  2023cites this paper
• Muramyl dipeptide-based analogs as potential anticancer compounds: Strategies to improve selectivity, biocompatibility, and efficiency

  2022cites this paper
• Targeting the innate immune system with nanoparticles for cancer immunotherapy.

  2022cites this paper
• Regulation of Immune Homeostasis via Muramyl Peptides-Low Molecular Weight Bioregulators of Bacterial Origin

  2022cites this paper
• Novel Scaffolds for Modulation of NOD2 Identified by Pharmacophore-Based Virtual Screening

  2022cites this paper
• Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their In Vivo Adjuvant Activity

  2021cites this paper
• The Role of the Bacterial Muramyl Dipeptide in the Regulation of GLP-1 and Glycemia

  2020cites this paper
• Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma.

  2020cites this paper
• Correction to: Current Advances in Osteosarcoma.

  2020cites this paper
• Chronic myelogenous leukemia Chronic myeloid leukemia stem cells

  2019cites this paper
• Translation of peptidoglycan metabolites into immunotherapeutics

  2019cites this paper
• Chronic myeloid leukemia stem cells

  2019cites this paper
• Harnessing the untapped potential of nucleotide‐binding oligomerization domain ligands for cancer immunotherapy

  2018cites this paper
• A cell‐based test system for the assessment of pharmacokinetics of NOD1 and NOD2 receptor agonists

  2018cites this paper
• Strengthening peptide-based drug activity with novel glyconanoparticle

  2018cites this paper
• The biology of bacterial peptidoglycans and their impact on host immunity and physiology

  2014cites this paper
• Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.

  2014cites this paper
• Immunomodulation by Bacteria and Their Products

  2012cites this paper
• Application of Liposomes for Construction of Vaccines

  2012cites this paper
• New muramyl dipeptide (MDP) mimics without the carbohydrate moiety as potential adjuvant candidates for a therapeutic hepatitis B vaccine (HBV)

  2011cites this paper
• Identification of SARS-COV Spike Protein-Derived and HLA-A2-Restricted Human CTL Epitopes by Using a New Muramyl Dipeptide-Derivative Adjuvant

  2010cites this paper
• Effect of muramyl peptides on mitochondrial respiration †

  2009cites this paper
• Screening for Potential Adjuvants Administered by the Pulmonary Route for Tuberculosis Vaccines

  2009cites this paper
• Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2.

  2008cites this paper
• NOD2, the gene responsible for familial granulomatous uveitis, in a mouse model of uveitis.

  2008cites this paper
• A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen.

  2005cites this paper
• Muramyl dipeptide bound to poly-l-lysine substituted with mannose and gluconoyl residues as macrophage activators

  2005cites this paper
• Some cellular and pathophysiological correlates of the inflammatory effects of a synthetic immunomodulatory agent, muramyl dipeptide (MDP)

  2005cites this paper
• Efficacy of human beta-casein fragment (54-59) and its synthetic analogue compound 89/215 against Leishmania donovani in hamsters.

  2004cites this paper
• Inhibition of murine hepatic tumor growth by liposomes containing a lipophilic muramyl dipeptide

  2004cites this paper
• Selective macrophage activation by muramyldipeptide bound to monoclonal antibodies specific for mouse tumor cells

  2004cites this paper
• Pharmacokinetics and feeding responses to muramyl dipeptide in rats.

  2003cites this paper
• Profiling and Trace Detection of Bacterial Cellular Carbohydrates

  2002cites this paper
• Glycomicrobiology

  2002cites this paper
• Prote in-load ed poly ( e-caprolac ton e ) m ic ropartic le s

  2000cites this paper
• Failure To Detect Muramic Acid in Normal Rat Tissues but Detection in Cerebrospinal Fluids from Patients with Pneumococcal Meningitis

  2000cites this paper
• Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. I. In vitro characterization.

  2000cites this paper
• Macrophage Activation by a Lipophilic Derivative of Muramyldipeptide within Nanocapsules: Investigation of the Mechanism of Drug Delivery

  1999cites this paper
• Protein-loaded poly(epsilon-caprolactone) microparticles. II. Muramyl dipeptide for oral controlled release of adjuvant.

  1999cites this paper
• MDP-Lysによるハムスター骨肉腫に対する肺転移抑制効果とその至適投与量(第2報)

  1998cites this paper
• Lipophilic drug derivatives in liposomes

  1998cites this paper
• CHAPTER 2.3 – Systemic activation of macrophages by liposomes containing synthetic immunomodulators for treatment of metastatic disease

  1998cites this paper
• Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators.

  1998cites this paper
• Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines.

  1997cites this paper
• Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro.

  1997cites this paper
• Relationship between NO-synthase activity and TNF-alpha secretion in mouse macrophage lines stimulated by a muramyl peptide entrapped in nanocapsules.

  1996cites this paper
• Synthesis and immunostimulating properties of lipophilic ester and ether muramyl peptide derivatives.

  1996cites this paper
• Liposomal phosphatidylserine inhibits tumor cytotoxicity of liver macrophages induced by muramyl dipeptide and lipopolysaccharide.

  1996cites this paper
• Distinctive immunomodulating properties and interactivity with model membranes and cells of two homologous muramyl dipeptide derivatives differing by their lipophilicity.

  1996cites this paper
• Absolute identification of muramic acid, at trace levels, in human septic synovial fluids in vivo and absence in aseptic fluids

  1996cites this paper
• Leishmania donovani in hamsters: Stimulation of non-specific resistance by novel lipopeptides and their effect in antileishmanial therapy

  1995cites this paper
• Liposome-encapsulated Muramyl Tripeptide Phosphatidylethanolamine for the Treatment of Feline Mammary Adenocarcinoma-A Multicenter Randomized Double-blind Study

  1995cites this paper
• Synthesis of Phthalimido‐Desmuramylpeptide Analogues as Potential Immunomodulating Agents

  1995cites this paper
• Effects of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen.

  1995cites this paper
• Clinical application of phospholipid liposomes containing macrophage activators for therapy of cancer metastasis

  1994cites this paper
• Therapy of cancer metastasis by systemic activation of macrophages.

  1994cites this paper
• Induction of Serum Tumor Necrosis Factor-alpha and Interleukin-6 Activity by Liposome-encapsulated Muramyl Tripeptide-phosphatidylethanolamine (L-MTP-PE) in Normal Cats

  1994cites this paper
• Secretion pattern of the rat liver macrophage population following activation with liposomal muramyl dipeptide in vivo and in vitro.

  1994cites this paper
• Anti-metastatic activity of MDP-L-alanyl-cholesterol incorporated into various types of nanocapsules.

  1994cites this paper
• Disposition of MK-852, a fibrinogen receptor antagonist, in rats and dogs.

  1994cites this paper
• Effect of Liposome-Muramyl Tripeptide Combined with Recombinant Canine Granulocyte Colony-Stimulating Factor on Canine Monocyte Activity

  1994cites this paper
• Tumor Cell Binding and Induction of Endothelial Cell Tumoricidal Activity In Vitro by Muramyl Dipeptide Is Enhanced by Liposomal Encapsulation

  1994cites this paper
• Absorption of peptide and peptidomimetic drugs.

  1994cites this paper
• Improved intracellular delivery of a muramyl dipeptide analog by means of nanocapsules.

  1994cites this paper
• Immunization against Echis ocellatus (carpet viper) venom using liposomes incorporating immunostimulants: role of lipopolysaccharide in conferring protection in a mouse model.

  1993cites this paper
• Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.

  1993cites this paper
• Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide

  1993cites this paper
• Liposomal Applications to Cancer Therapy

  1993cites this paper
• Modification of reticuloendothelial function by muramyl dipeptide-encapsulated liposomes in jaundiced rats treated with biliary decompression.

  1993cites this paper
• Recurrent anterior uveitis induced by multiple systemic injections of muramyl dipeptide.

  1993cites this paper
• Muramyl Peptides Augment the In Vitro and In Vivo Cytostatic Activity of Canine Plastic-Adherent Mononuclear Cells Against Canine Osteosarcoma Cells

  1993cites this paper
• Biodegradable nanocapsules containing a lipophilic immunomodulator: drug retention and tolerance towards macrophages in vitro.

  1993cites this paper
• Pharmacokinetics of an immunomodulator peptidoglycan monomer in mice after intravenous administration.

  1993cites this paper
• Targeting of muramyl dipeptide to macrophages by gelatin conjugation to enhance their in vivo antitumor activity

  1993cites this paper
• T-cell-dependent immunobiological activity of a desmuramyl analog of muramyl dipeptide, adamantylamide dipeptide (AdDP), and D-isoglutamine.

  1993cites this paper
• Adjuvants--a balance between toxicity and adjuvanticity.

  1993cites this paper
• Activation of mouse macrophages by muramyl dipeptide coupled with an anti-macrophage monoclonal antibody.

  1992cites this paper
• Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.

  1992cites this paper
• Differences in proinflammatory activity of several immunomodulatory derivatives of muramyl dipeptide (MDP) with special reference to the mechanism of the MDP effects

  1992cites this paper
• Liposomal delivery of biological response modifiers to macrophages

  1991cites this paper
• Anti-metastatic activity in vivo of MDP-L-alanyl-cholesterol (MTP-Chol) entrapped in nanocapsules.

  1991cites this paper
• In Vitro Evaluation of Macrophage Mediated Host Defenses against Neoplastic Disease

  1991cites this paper
• Leishmania donovani in hamsters: Stimulation of non-specific resistance by some novel glycopeptides and impact on therapeutic efficacy

  1991cites this paper
• In vitro stimulation of immune functions by lipids derived from macrophages exposed to bacterial peptidoglycan.

  1991cites this paper
• Rapid elimination of a synthetic adjuvant peptide from the circulation after systemic administration and absence of detectable natural muramyl peptides in normal serum at current analytical limits

  1991cites this paper
• In vivo modulation of atypical mycobacterial infection: adjuvant therapy increases resistance to Mycobacterium avium by enhancing macrophage effector functions.

  1991cites this paper
• Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice.

  1991cites this paper
• Enhancing effect of cetylmannoside on targeting of liposomes to Kupffer cells in rats

  1991cites this paper
• Therapy of Murine Liver Metastases by Administration of MDP Encapsulated in Liposomes

  1990cites this paper
• Syntheses of polymeric vesicles containing partial structures of N-acetyl-muramyl-dipeptide (MDP).

  1990cites this paper
• Intracisternal administration of Mycobacterium tuberculosis potentiates the delayed type hypersensitivity in guinea-pigs.

  1990cites this paper
• Macrophage activation by muramyl dipeptide bound to neoglycoproteins and glycosylated polymers: cytotoxic factor production.

  1990cites this paper
• Macrophages and cancer

  1990cites this paper
• Role of bacterial debris in inflammatory diseases of the joint and eye

  1990cites this paper
• [Activation of cellular immunity in mice under normal conditions and in tumor growth during treatment with glucosaminyl muramyl dipeptide].

  1990cites this paper
• The Characterization of Immunotherapeutic Agents

  1990cites this paper
• Synthesis of muramoyltripeptides and their isotope-labeled analogues

  1990cites this paper
• Uptake of muramyl dipeptide fluorescent congeners by normal rabbit bronchoalveolar lavage cells: a study using flow cytometry.

  1990cites this paper
• Modulation of the blood-aqueous barrier by gram positive and gram negative bacterial cell wall components in the rat and rabbit.

  1990cites this paper